(Q44833579)

6 December 2017

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery (English)

1 reference

6 December 2017

1 reference

Lindy L Thomsen

1

1 reference

6 December 2017

Peter Topley

2

1 reference

6 December 2017

Maria G Daly

3

1 reference

6 December 2017

Sara J Brett

4

1 reference

6 December 2017

John P Tite

5

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

22

1 reference

6 December 2017

1799-1809

1 reference

6 December 2017

13-14

1 reference

6 December 2017

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Genetic adjuvants for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Imiquimod and resiquimod as novel immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Cytokine induction by the immunomodulators imiquimod and S-27609

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Early commitment of adoptively transferred CD4+ T cells following particle-mediated DNA vaccination: implications for the study of immunomodulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

The immune response modifier resiquimod mimics CD40-induced B cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Cytokine induction in mice by the immunomodulator imiquimod.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Toll signaling pathways in the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

Imiquimod applied topically: a novel immune response modifier and new class of drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.09.052

1 reference

6 December 2017

1 reference